

Review Article

Extracellular regulation of BMP signaling: welcome to the matrix

Georg Sedlmeier¹ and Jonathan P. Sleeman^{1,2}¹Centre for Biomedicine and Medical Technology Mannheim, Medical Faculty Mannheim, University Heidelberg, 68167 Mannheim, Germany and ²Institute for Toxicology and Genetics, Karlsruhe Institute of Technology Campus Nord, 76021 Karlsruhe, GermanyCorrespondence: Georg Sedlmeier (georg.sedlmeier@medma.uni-heidelberg.de) or Jonathan P. Sleeman (jonathan.sleeman@medma.uni-heidelberg.de)

Given its importance in development and homeostasis, bone morphogenetic protein (BMP) signaling is tightly regulated at the extra- and intracellular level. The extracellular matrix (ECM) was initially thought to act as a passive mechanical barrier that sequesters BMPs. However, a new understanding about how the ECM plays an instructive role in regulating BMP signaling is emerging. In this mini-review, we discuss various ways in which the biochemical and physical properties of the ECM regulate BMP signaling.

Introduction

Bone morphogenetic proteins (BMPs) belong to the superfamily of transforming growth factor- β proteins. More than 20 family members have been described. Initially identified for their osteogenic activity, BMPs play important roles in development and tissue homeostasis. Misbalances in BMP signaling are commonly observed in diseases such as cancer and fibrosis [1]. Therefore, tight extracellular and intracellular regulation of BMP signaling is critical.

BMPs are evolutionarily conserved secreted growth factors that, in vertebrates, are divided into several subgroups based on phylogenetic analysis [2] (Table 1). BMPs are translated as pre-proteins with a prodomain. Within the endoplasmic reticulum, prodomains facilitate homo- and heterodimerization of BMPs via disulfide assembly [3]. Following secretion into the extracellular space, BMP dimers bind to BMP type II receptors, which then heterodimerize with type I receptors (Figure 1A,B). There are three type I receptors and three type II receptors (Table 1) [4]. Following heterodimerization, type I receptors are phosphorylated by type II receptors and subsequently activate the receptor-regulated R-Smads (Smad1, 5 and 8) through phosphorylation [5]. Phosphorylated Smad1, 5 and 8 heterodimers form a complex with the only common mediator Smad (Co-Smad) Smad4. Following nuclear translocation of the R-Smad/Co-Smad complex, BMP target gene expression is induced [5].

Intracellularly, BMP signaling is negatively regulated by the inhibitory Smads (I-Smads) Smad6 and Smad7, which compete with Smad4 for binding to R-Smads [6], or by Smad ubiquitin ligases of the Smurf family [7]. Extracellularly, a variety of secreted antagonists, such as noggin and chordin, bind to BMPs and inhibit their ability to interact with BMP receptors (BMPRs) (Figure 1C) [8]. BMP antagonists are classified into three families [9] (Table 1). These antagonists bind distinct BMPs with varying degrees of affinity and thereby selectively modulate BMP signaling responses [10]. Other extracellular BMP-binding proteins form soluble shuttling complexes with BMPs, fostering increased diffusion rates and ranges (Figure 1D,E and Table 1) [11]. The activity, bioavailability and diffusion of extracellular BMP signaling agonists and antagonists are further regulated by extracellular matrix (ECM) components [12].

The ECM is the noncellular compartment that surrounds cells, and includes basement membranes and the interstitial matrix. It comprises a variety of proteins and polysaccharides. Each tissue has its unique composition of ECM molecules. These components can often directly bind to and interact with growth factors, receptors and co-receptors through their biochemical properties [13]. On the one hand, these interactions can lead to simple sequestration of growth factors in the extracellular milieu.

Received: 24 August 2016

Revised: 13 October 2016

Accepted: 24 October 2016

Version of Record published:
15 February 2017

Table 1 Mammalian bone morphogenetic protein signaling molecules and their homologs in *Drosophila melanogaster*

The table is based on the NCBI HomoloGene database. Abbreviations: ACVR, activin A receptor; ALK, activin receptor-like kinase; BMP, bone morphogenetic protein; DAN, differential screening selected gene abberative in neuroblastoma; GDF, growth differentiation factor.

Mammalian	<i>Drosophila melanogaster</i>
BMPs	
BMP2/4	Decapentaplegic (Dpp)
BMP5/6/7/8	Glass bottom boat (Gbb), Screw (Scw)
BMP9/BMP10	
BMP12/13/14 (GDF5/6/7)	
BMPRs	
<i>Type I receptors</i>	
ACVR1 (ALK-2)	Saxophone (Sax)
BMPR1A (ALK-3)	Wishful thinking (Wit)
BMPR1B (ALK-6)	Thick veins (Tkv)
<i>Type II receptors</i>	
ACVR2A	Punt (Put)
ACVR2B	
BMPR2	
BMP antagonists	
Chordin (CHRD)	Short gastrulation (Sog)
Noggin (NOG)	
<i>DAN family</i>	
Gremlin 1 (GREM1)	
Cerberus 1 (CER1)	
Neuroblastoma 1 (NBL1)	
Protein related to DAN and cerberus (PRDC)	
BMP-binding proteins	
BMP-binding endothelial regulator (BMPER)	Crossveinless-2 (Cv-2)
Twisted gastrulation BMP signaling modulator (Twsg1)	Twisted gastrulation (Tsg)

On the other hand, ECM components can play an instructive role in signaling by controlling the level, location and kinetics of growth factor presentation to their cognate receptors [14]. Additionally, the ECM is a structural determinant with defined physical properties. The molecular composition of the ECM determines its stiffness, elasticity and porosity, which directly has an impact on the diffusion of macromolecules [15]. Cells are capable of sensing these physical properties and reacting with distinct cellular responses, for example modified differentiation, which is referred to as mechanosignaling [16].

In the following, we discuss the biochemical and physical properties of the ECM and their role in regulating BMP signaling. Figures 1 and 2 provide a direct comparison of the current view of BMP signaling without and with the ECM present, respectively.

Biochemical properties of the ECM: from passive sequestration to an instructive role in BMP signaling

Several ECM components are capable of binding directly to BMP signaling molecules and thereby modulating their ability to successfully initiate BMP signaling in various ways [12]. The interaction of BMPs with ECM molecules depends on their distinct biochemical properties.




Figure 1. BMP signaling in the absence of regulation by ECM components.

(A) Following successful dimerization, BMP dimers are secreted and diffuse into the extracellular space. (B) BMP dimers bind to BMP type II receptors that subsequently heterodimerize and transphosphorylate BMP type I receptors. R-Smads become phosphorylated and form a complex with Co-Smads, which will be translocated to the nucleus to induce target gene expression. Smad signaling is intracellularly counteracted by I-Smads and Smurf proteins. (C) Extracellularly, BMP signaling is inhibited by BMP antagonists, including noggin and chordin. (D) Ternary complex formation of Sog/Dpp/Tsg allows for long distance shuttling of Dpp. (E) Tolloid-mediated cleavage of Sog releases Dpp from the ternary complex and it is free to act at a distant site. (F) Receptor-mediated endocytosis of the BMP ligand/receptor complex. (G) CD44 binds Smad1 close to the cell membrane to facilitate Smad1 phosphorylation by BMPRs. (H) Integrins assist BMPR-mediated activation of R-Smads. (I) In the absence of extracellular signals, BMPRs and integrins do not engage without ligand binding.

ECM components bind to and sequester BMP signaling molecules and regulate their activity

In the early 1990s, it was discovered that BMPs bind with various degrees of affinity to several ECM components, including laminins and collagens [17]. Subsequent structural analyses revealed that the N-terminal prodomain of collagen type IIA binds BMP2 [18], whereas the C-terminal part of collagen type IV binds BMP4 [19].

Many ECM components are proteoglycans (PGs), proteins that are covalently linked to glycosaminoglycan (GAG) chains such as heparin, heparan sulfate, chondroitin sulfate (CS), dermatan sulfate (DS) and keratan sulfate. BMPs are capable of binding to heparins via a stretch of basic amino acid residues in the N-terminal region [20]. Negatively charged heparan sulfate proteoglycans (HSPGs), in particular, can bind to the N-terminal basic moiety of BMPs, [21] and it has been suggested that the degree of sulfation has an impact on the strength of the electrostatic interactions between HSPGs and BMPs [22]. However, binding of BMPs to HSPGs does not entirely depend on sulfated GAGs, as the protein core of the drosophila GPI-linked HSPG dally directly binds to BMP4 [23].

Small leucine-rich proteoglycans (SLRP) are ECM proteoglycans that consist of a protein core made up of leucine-rich repeats to which GAG chains of either CS or DS are attached [24]. Three members of the SLRP




Figure 2. Regulation of BMP signaling by ECM components.

(A) ECM components inhibit the diffusion of BMP dimers into the extracellular space resulting in increased pericellular BMP levels that could result in enhanced autocrine BMP signaling. (B) Sequestration of BMPs by fibrillins prevents their binding to BMPRs. (C) SLRPs, such as biglycan and tsukushi, can bind to BMP antagonists and promote their inhibitory function of BMPs. (D) Collagen IV assists ternary complex formation of Sog/Dpp/Tsg by acting as a scaffold. (E) Sog cleavage by tolloid is assisted by collagen IV. (F) COMP prevents receptor-mediated endocytosis by bridging BMPs with collagens or proteoglycans. (G) Hyaluronic acid assists cluster formation of CD44, which binds Smad1 close to the cell membrane to facilitate its phosphorylation by BMPRs. (H) Collagen IV promotes the binding of integrins to BMPRs and thereby enhances BMP signaling. (I) Mechanic stress such as oscillatory shear stress or increased stiffness of the ECM [schematically represented as external force (F)] can induce complex formation of BMPRs with integrins, which induces Smad1 phosphorylation through Shc/Fak/Erk signaling in the absence of BMP ligands.

family, decorin, biglycan and tsukushi, can regulate BMP signaling extracellularly in different ways. All three SLRPs can exhibit inhibitory functions on BMP signaling. Decorin was demonstrated to inhibit BMP7-mediated signaling and thereby to antagonize nephron progenitor cell differentiation [25]. In addition, both decorin and biglycan have been shown to interfere with BMP2 activity [26]. BMP4 signaling can be inhibited by biglycan and tsukushi through the modulation of antagonist-mediated inhibition of BMP signaling. While biglycan promotes the binding of the BMP antagonist chordin to BMP4, which results in a more efficient inhibition of BMP4 signaling [27], the inhibition-promoting effect of tsukushi is due to its binding to both BMP4 and chordin, leading to ternary complexes of tsukushi, BMP4 and chordin, in which BMP4 signaling is co-operatively inhibited (Figures 1 and 2C) [28].

In contrast with the inhibitory function of biglycan on extracellular BMP signaling described above, other reports indicate a promoting function of biglycan on BMP signaling [29,30]. Biglycan was shown to have a promoting effect on BMP2 signaling *in vitro* in C2C12 myoblastic cells and *in vivo* in a rat mandibular defect model [29]. This promoting effect on BMP signaling was further enhanced by deglycanation (removal of GAG chains) of biglycan [29]. This suggests that GAG chains of biglycan are implicated in regulating the intensity of BMP2 signaling. In line with this finding, GAG chains of biglycan were found to be crucial for its stimulating

function on BMP4 signaling in murine calvarial cells [30]. In agreement with this observation, it was found that oversulfated CS, which is one of the main GAG chains of biglycan and other SLRPs, enhances BMP4-mediated osteogenesis of MC3T3-E1 osteoblastic cells [31]. However, another study found that oversulfated CSs themselves are capable of inducing osteogenic differentiation of human mesenchymal stromal cells independently of BMPs [32]. Therefore, the role of biglycan GAG chains in regulating BMP signaling activity needs further evaluation and is likely to be dependent on the cell type and BMPs investigated. In addition, more studies are needed to determine the role of GAG chains and their sulfation state in order to understand how extracellular proteoglycans, such as biglycan, bind to and interact with BMP signaling molecules.

Fibrillins are other major components of the ECM that bind to BMPs [33]. Fibrillins 1, 2 and 3 are self-assembling glycoproteins that aggregate to form microfibrils of 10–12 nm in diameter within the extracellular space, and which are critically involved in determining tissue elasticity and stiffness [34]. Binding of BMPs to fibrillins is mainly mediated by the BMP prodomain [35,36]. Prodomain binding to the N-terminal part of fibrillins can sequester BMPs within the ECM (Figures 1 and 2B) [35].

Sequestration of BMPs by the ECM within the extracellular space can inhibit binding to BMPRs. For example, binding of the BMP7 prodomain to fibrillin-1 causes a conformational change that prevents BMP7 from binding to its receptors [37]. However, BMPs can later be released through matrix remodeling, so that BMP sequestration serves a reservoir function [38]. Thus, the ECM regulates both the bioavailability and activity of BMPs secreted into the extracellular space.

ECM-assisted formation of multicomponent complexes that foster short- and long-range BMP signaling

A growing body of evidence indicates that BMP signaling is regulated by multicomponent complexes in which the ECM plays an instructive role by acting as a scaffold that directly shapes the intensity and duration of BMP signaling. For example, cartilage oligomeric matrix protein (COMP), an ECM glycoprotein, sustains BMP signaling by acting as a co-receptor that bridges BMPs with other ECM components such as collagen [39]. The authors suggest that COMP could assist complex formation of BMP2 with PGs or collagens, and thereby prevent endocytosis and degradation of BMP2/BMPR complexes (Figures 1 and 2F) [39]. Moreover, the ability of COMP to foster BMP signaling has been confirmed in an *in vivo* rat model of spinal fusion, where COMP was found to enhance bone-forming activity of low-dose recombinant BMP2 [40]. Structural analysis demonstrated that COMP binds directly to BMP2 via its C-terminal domain [41]. However, in this study, COMP was found to prevent BMP2 from binding to its receptors and thereby inhibit BMP2-mediated vascular smooth muscle calcification [41]. Therefore, the role of COMP in regulating BMP signaling appears to be context-dependent. Further studies are needed to determine whether COMP could be used for enhancing BMP signaling *in vivo*.

Another example is provided by hyaluronic acid (HA), a high molecular mass GAG that exists as a free polysaccharide in the ECM. The HA cell surface receptor CD44 interacts intracellularly with Smad1, which promotes BMP7 signaling responses (Figure 1G) [42]. Removal of pericellular HA from murine chondrocytes by hyaluronidase treatment was found to decrease BMP7-induced Smad1 phosphorylation [43]. HA-assisted BMP7 signaling is only effective at lower BMP7 concentrations and is not required when higher concentrations of BMP7 are present [43]. As HA is critical for CD44 clustering at the cell surface [44], HA could conceivably promote cluster formation of CD44/Smad1 close to the cell membrane and thereby facilitate BMPR-mediated phosphorylation of Smad1 (Figure 2G). Taken together, these findings suggest an instructive role for HA on BMP signaling that is mediated through CD44.

Other studies indicate that integrins can co-operate with BMPRs in an ECM-dependent manner, which augments BMP signaling. For example, the binding of the drosophila BMP2/4 homolog Decapentaplegic (Dpp) or human BMP4 to collagen type IV promotes BMP signaling in a manner that requires the binding of the collagen type IV to integrins [19,45]. Here, collagen acts as a scaffold that recruits integrins into a complex with the BMPR, which results in elevated levels of BMP signaling (Figures 1 and 2H). Integrin signaling is required for this effect. Other studies suggest that fibronectin-bound BMP2 can regulate a functional interaction between BMPRs and $\alpha\beta 3$ integrins [46]. In this study, $\alpha\beta 3$ integrins stimulated BMP signaling through fostering BMPR-induced Smad phosphorylation directly, as well as by suppressing GSK3 activity, leading to increased Smad stability.

Within the extracellular space, several BMP-binding proteins form complexes with BMPs that increase their solubility and thus act as shuttles for BMPs to travel over longer distances [12]. In *Drosophila*, the binding proteins short gastrulation (Sog) and twisted gastrulation (Tsg) form a soluble ternary complex with Dpp (Figure 1D) [47]. This complex formation can be facilitated by ECM components. Collagen IV was shown to act as a scaffold for ternary complex formation of Sog/Dpp/Tsg, in which Sog/Dpp is first complexed to collagen IV and the subsequent binding of Tsg releases the ternary complex Sog/Dpp/Tsg from collagen IV, so that it can freely move (Figure 2D) [48]. To act at a distant site, Dpp has to be released from the ternary complex. This release is mediated through tollid metalloproteinase cleavage of Sog, which again is assisted by collagen IV that acts as a scaffold for the Sog–tollid interaction (Figures 1 and 2E) [49].

Taken together, these examples demonstrate an important role for a variety of ECM components that act as scaffolds, which promote the formation of multiprotein complexes that regulate BMP signaling.

Physical properties of the ECM: BMP concentration gradients and mechanosignaling

Physical properties of the ECM include stiffness, elasticity and porosity, which can have an impact on BMP signaling, for example through the shaping of BMP concentration gradients. In addition, cells sense the mechanical properties of the ECM through mechanoreception, which can further regulate BMP signaling.

ECM-shaped concentration gradients of BMP molecules

Restricted diffusion in the ECM is critical for BMP gradient formation, for example during development [50]. These gradients can be determined in part through the biochemical interactions between ECM components and BMPs, as outline above. As an example, collagen IV immobilizes Dpp, whereas a Dpp mutant lacking collagen IV binding motifs diffuses over longer ranges *in vivo* [48]. However, in addition to inhibiting BMP diffusion through biochemical interactions, the ECM constitutes a mechanical barrier through which the diffusion of BMPs is hindered (Figures 1 and 2A) [15]. The diffusion coefficient of green fluorescent protein (GFP)–Dpp in the wing imaginal disc is $0.10 \pm 0.05 \mu\text{m}^2/\text{s}$ [51], which is highly reduced compared with that of GFP in free solution (diffusion coefficient of $87 \mu\text{m}^2/\text{s}$) [52]. Consistently, a secreted form of GFP fails to form a concentration gradient [50]. Several studies suggest a restricted diffusion of BMPs along ECM components such as HSPGs [53,54], which may be caused, at least in part, by transient reversible interactions between these ECM components and BMPs. ECM porosity may also regulate the diffusion rates of BMPs in different ECM contexts.

In addition to helping form gradients, reduced diffusion rates of secreted BMPs, in particular ECM contexts, could lead to local accumulation of BMPs in the ECM around cells that secrete BMPs. Increased pericellular levels of BMPs would, in turn, activate autocrine BMP signaling, if the producing cells also express the appropriate BMPRs. Thus, ECM microenvironments that reduce BMP diffusion would be predicted to sensitize cells to autocrine BMP signaling.

ECM-mediated mechanotransduced BMP signaling

Cells respond to the physical properties of the ECM surrounding them through mechanoreception. Smad1/5/8 phosphorylation is observed upon compressive strain in osteoblasts [55] and upon oscillatory shear stress (OSS) in endothelial cells independent of BMP ligand binding (Figures 1 and 2I) [56]. Furthermore, Smad1/5/8 phosphorylation upon OSS in endothelial cells depends on the interaction between BMPRII and $\alpha_v\beta_3$ integrin, which form a mechanoreceptor complex that mediates Smad1/5/8 phosphorylation through the Shc/Fak/Erk pathway [57]. Bone marrow mesenchymal stem cells embedded in soft substrates exhibit increased β_1 integrin-mediated internalization of BMPRII compared with stiff substrates, which determines their differentiation fate [58]. Accordingly, BMPRII interacts with the integrin β_1 subunit to induce Smad1/5 signaling in response to increased substrate stiffness [59]. Mechanical regulation of BMP signaling is also relevant *in vivo*, as mechanical load exhibited a stimulatory effect on BMP2-mediated bone healing in rats [60]. Thus, ECM stiffness directly regulates BMP signaling, with higher degrees of stiffness stabilizing BMPR/integrin complexes (Figure 2I). These findings further underscore the importance of integrins in regulating cellular response to BMPs, as integrin and BMP signaling converge to regulate cellular responses to the mechanical properties of the ECM.

Conclusion

BMP signaling clearly involves more than just BMPs and their receptors. Here, we have reviewed how the composition of the ECM and its biochemical and physical properties act in a variety of ways to positively or negatively regulate the activation of BMPs, and show that the ECM is a dynamic and instructive regulator of BMP signaling. In addition to sequestering BMPs and their antagonists, ECM components act as important scaffolds that assist the formation of multiprotein complexes that regulate BMP signaling. A further level of complexity that has not been fully addressed here is the ability of a variety of cell surface molecules to act *in cis* and cross-regulate BMP signaling [12]. Clearly, the ECM is capable of regulating the function of some of these *cis*-acting surface proteins; for example, CD44 and specific integrins as outlined above. In future studies, it will be interesting to investigate whether the ECM also has an impact on the activity of co-receptors for BMP signaling such as repulsive guidance molecules [61], neogenin [62], betaglycan (T β RIII) [63] and endoglin (CD105) [64]. It will also be important to translate findings regarding the importance of ECM/BMP interactions made solely with cultured cells to the *in vivo* setting, where a complex ECM containing multiple components that can each regulate BMP signaling is present. Furthermore, many BMP antagonists bind to cell surface HSPGs via the GAG moiety [65,66]. We note that many ECM components are also HSPGs, so tethering of BMP antagonists to the ECM may add a further level of regulation. Thus, despite great advances in understanding the extracellular regulation of BMP signaling by the ECM, much remains to be discovered.

Abbreviations

BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein receptor; COMP, cartilage oligomeric matrix protein; CS, chondroitin sulfate; Dpp, decapentaplegic; DS, dermatan sulfate; ECM, extracellular matrix; GAG, glycosaminoglycan; GFP, green fluorescent protein; GPI, glycosylphosphatidylinositol; HA, hyaluronic acid; HSPG, heparan sulfate proteoglycans; I-Smads, inhibitory Smads; OSS, oscillatory shear stress; PG, proteoglycan; SLRP, small leucine-rich proteoglycans; Smad, mothers against decapentaplegic; Sog, short gastrulation; TGF- β , transforming growth factor- β ; Tsg, twisted gastrulation.

Funding

This work was supported by a grant from the Deutsche Forschungsgemeinschaft (German Research Council) within the framework [GRK2099] “Hallmarks of Skin Cancer”.

Competing Interests

The Authors declare that there are no competing interests associated with the manuscript.

References

- 1 Wang, R.N., Green, J., Wang, Z., Deng, Y., Qiao, M., Peabody, M. et al. (2014) Bone morphogenetic protein (BMP) signaling in development and human diseases. *Genes Dis.* **1**, 87–105 PMID:25401122
- 2 Mueller, T.D. and Nickel, J. (2012) Promiscuity and specificity in BMP receptor activation. *FEBS Lett.* **586**, 1846–1859 PMID:22710174
- 3 Gray, A.M. and Mason, A.J. (1990) Requirement for activin A and transforming growth factor — beta 1 pro-regions in homodimer assembly. *Science* **247**, 1328–1330 PMID:2315700
- 4 Miyazono, K., Kamiya, Y. and Morikawa, M. (2010) Bone morphogenetic protein receptors and signal transduction. *J. Biochem.* **147**, 35–51 PMID:19762341
- 5 Massagué, J. (1996) TGF β signaling: receptors, transducers, and Mad proteins. *Cell* **85**, 947–950 PMID:8674122
- 6 Hata, A., Lagna, G., Massagué, J. and Hemmati-Brivanlou, A. (1998) Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. *Genes Dev.* **12**, 186–197 PMID:9436979
- 7 Zhu, H., Kavsak, P., Abdollah, S., Wrana, J.L. and Thomsen, G.H. (1999) A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. *Nature* **400**, 687–693 PMID:10458166
- 8 Mulloy, B. and Rider, C.C. (2015) The bone morphogenetic proteins and their antagonists. *Vitam. Horm.* **99**, 63–90 PMID:26279373
- 9 Walsh, D.W., Godson, C., Brazil, D.P. and Martin, F. (2010) Extracellular BMP-antagonist regulation in development and disease: tied up in knots. *Trends Cell Biol.* **20**, 244–256 PMID:20188563
- 10 Zimmerman, L.B., De Jesús-Escobar, J.M. and Harland, R.M. (1996) The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. *Cell* **86**, 599–606 doi:10.1016/S0092-8674(00)80133-6
- 11 Ben-Zvi, D., Shilo, B.-Z., Fainsod, A. and Barkai, N. (2008) Scaling of the BMP activation gradient in *Xenopus* embryos. *Nature* **453**, 1205–1211 doi:10.1038/nature07059
- 12 Umulis, D., O'Connor, M.B. and Blair, S.S. (2009) The extracellular regulation of bone morphogenetic protein signaling. *Development* **136**, 3715–3728 doi:10.1242/dev.031534
- 13 Schultz, G.S. and Wysocki, A. (2009) Interactions between extracellular matrix and growth factors in wound healing. *Wound Repair Regen.* **17**, 153–162 doi:10.1111/j.1524-475X.2009.00466.x

- 14 Ramirez, F., Sakai, L.Y., Rifkin, D.B. and Dietz, H.C. (2007) Extracellular microfibrils in development and disease. *Cell Mol. Life Sci.* **64**, 2437–2446 PMID:17585369
- 15 Kihara, T., Ito, J. and Miyake, J. (2013) Measurement of biomolecular diffusion in extracellular matrix condensed by fibroblasts using fluorescence correlation spectroscopy. *PLoS ONE* **8**, e82382 PMID:24312418
- 16 Schedin, P. and Keely, P.J. (2011) Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. *Cold Spring Harb. Perspect. Biol.* **3**, a003228 PMID:20980442
- 17 Paralkar, V.M. (1992) Recombinant human bone morphogenetic protein 2B stimulates PC12 cell differentiation: potentiation and binding to type IV collagen. *J. Cell Biol.* **119**, 1721–1728 PMID:1469059
- 18 Zhu, Y., Oganessian, A., Keene, D.R. and Sandell, L.J. (1999) Type IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-beta1 and BMP-2. *J. Cell Biol.* **144**, 1069–1080 PMID:10085302
- 19 Wang, X., Harris, R.E., Bayston, L.J. and Ashe, H.L. (2008) Type IV collagens regulate BMP signalling in *Drosophila*. *Nature* **455**, 72–77 doi:10.1038/nature07214
- 20 Ruppert, R., Hoffmann, E. and Sebald, W. (1996) Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. *Eur. J. Biochem.* **237**, 295–302 doi:10.1111/j.1432-1033.1996.0295n.x
- 21 Ohkawara, B., Iemura, S.-i., ten Dijke, P. and Ueno, N. (2002) Action range of BMP is defined by its N-terminal basic amino acid core. *Curr. Biol.* **12**, 205–209 doi:10.1016/S0960-9822(01)00684-4
- 22 Gandhi, N.S. and Mancera, R.L. (2012) Prediction of heparin binding sites in bone morphogenetic proteins (BMPs). *Biochim. Biophys. Acta Proteins Proteom.* **1824**, 1374–1381 doi:10.1016/j.bbapap.2012.07.002
- 23 Kirkpatrick, C.A., Knox, S.M., Staatz, W.D., Fox, B., Lercher, D.M. and Selleck, S.B. (2006) The function of a *Drosophila* glypican does not depend entirely on heparan sulfate modification. *Dev. Biol.* **300**, 570–582 PMID:17055473
- 24 Merline, R., Schaefer, R.M. and Schaefer, L. (2009) The matricellular functions of small leucine-rich proteoglycans (SLRPs). *J. Cell Commun. Signal.* **3**, 323–335 PMID:19809894
- 25 Fetting, J.L., Guay, J.A., Karolak, M.J., Iozzo, R.V., Adams, D.C., Maridas, D.E. et al. (2014) FOXD1 promotes nephron progenitor differentiation by repressing decorin in the embryonic kidney. *Development* **141**, 17–27 PMID:24284212
- 26 Bi, Y., Stuelten, C.H., Kilts, T., Wadhwa, S., Iozzo, R.V., Robey, P.G. et al. (2005) Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. *J. Biol. Chem.* **280**, 30481–30489 PMID:15964849
- 27 Moreno, M., Muñoz, R., Aroca, F., Labarca, M., Brandan, E. and Larrain, J. (2005) Biglycan is a new extracellular component of the Chordin-BMP4 signaling pathway. *EMBO J.* **24**, 1397–1405 PMID:15775969
- 28 Ohta, K., Lupo, G., Kuriyama, S., Keynes, R., Holt, C.E., Harris, W.A. et al. (2004) Tsukushi functions as an organizer inducer by inhibition of BMP activity in cooperation with chordin. *Dev. Cell* **7**, 347–358 PMID:15363410
- 29 Miguez, P.A., Terajima, M., Nagaoka, H., Mochida, Y. and Yamauchi, M. (2011) Role of glycosaminoglycans of biglycan in BMP-2 signaling. *Biochem. Biophys. Res. Commun.* **405**, 262–266 PMID:21219861
- 30 Ye, Y., Hu, W., Guo, F., Zhang, W., Wang, J. and Chen, A. (2012) Glycosaminoglycan chains of biglycan promote bone morphogenetic protein-4-induced osteoblast differentiation. *Int. J. Mol. Med.* **30**, 1075–1080 PMID:22895561
- 31 Miyazaki, T., Miyauchi, S., Tawada, A., Anada, T., Matsuzaka, S. and Suzuki, O. (2008) Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. *J. Cell. Physiol.* **217**, 769–777 PMID:18720384
- 32 Büttner, M., Möller, S., Keller, M., Huster, D., Schiller, J., Schnabelrauch, M. et al. (2013) Over-sulfated chondroitin sulfate derivatives induce osteogenic differentiation of hMSC independent of BMP-2 and TGF-β1 signalling. *J. Cell. Physiol.* **228**, 330–340 PMID:22718137
- 33 Ramirez, F. and Rifkin, D.B. (2009) Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. *Curr. Opin. Cell Biol.* **21**, 616–622 PMID:19525102
- 34 Jensen, S.A., Robertson, I.B. and Handford, P.A. (2012) Dissecting the fibrillin microfibril: structural insights into organization and function. *Structure* **20**, 215–225 PMID:22325771
- 35 Sengle, G., Charbonneau, N.L., Ono, R.N., Sasaki, T., Alvarez, J., Keene, D.R. et al. (2008) Targeting of bone morphogenetic protein growth factor complexes to fibrillin. *J. Biol. Chem.* **283**, 13874–13888 PMID:18339631
- 36 Sengle, G., Ono, R.N., Sasaki, T. and Sakai, L.Y. (2011) Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. *J. Biol. Chem.* **286**, 5087–5099 PMID:21135108
- 37 Wohl, A.P., Troilo, H., Collins, R.F., Baldock, C. and Sengle, G. (2016) Extracellular regulation of bone morphogenetic protein activity by the microfibril component fibrillin-1. *J. Biol. Chem.* **291**, 12732–12746 PMID:27059954
- 38 Nistala, H., Lee-Arteaga, S., Smaldone, S., Siciliano, G., Carta, L., Ono, R.N. et al. (2010) Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation. *J. Cell Biol.* **190**, 1107–1121 doi:10.1083/jcb.201003089
- 39 Ishida, K., Acharya, C., Christiansen, B.A., Yik, J.H.N., DiCesare, P.E. and Haudenschild, D.R. (2013) Cartilage oligomeric matrix protein enhances osteogenesis by directly binding and activating bone morphogenetic protein-2. *Bone* **55**, 23–35 doi:10.1016/j.bone.2013.03.007
- 40 Refaat, M., Klineberg, E.O., Fong, M.C., Garcia, T.C., Leach, J.K. and Haudenschild, D.R. (2016) Binding to COMP reduces the BMP2 dose for spinal fusion in a rat model. *Spine* **41**, E829–E836 doi:10.1097/BRS.0000000000001408
- 41 Du, Y., Wang, Y., Wang, L., Liu, B., Tian, Q., Liu, C.-j. et al. (2011) Cartilage oligomeric matrix protein inhibits vascular smooth muscle calcification by interacting with bone morphogenetic protein-2. *Circ. Res.* **108**, 917–928 doi:10.1161/CIRCRESAHA.110.234328
- 42 Peterson, R.S., Andhare, R.A., Rousche, K.T., Knudson, W., Wang, W., Grossfield, J.B. et al. (2004) CD44 modulates Smad1 activation in the BMP-7 signaling pathway. *J. Cell Biol.* **166**, 1081–1091 doi:10.1083/jcb.200402138
- 43 Luo, N., Knudson, W., Askew, E.B., Veluci, R. and Knudson, C.B. (2014) CD44 and hyaluronan promote the bone morphogenetic protein 7 signaling response in murine chondrocytes. *Arthritis Rheumatol.* **66**, 1547–1558 doi:10.1002/art.38388
- 44 Yang, C., Cao, M., Liu, H., He, Y., Xu, J., Du, Y. et al. (2012) The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. *J. Biol. Chem.* **287**, 43094–43107 PMID:23118219
- 45 Sawala, A., Scarcia, M., Sutcliffe, C., Wilcockson, S.G. and Ashe, H.L. (2015) Peak BMP responses in the *Drosophila* embryo are dependent on the activation of integrin signaling. *Cell Rep.* **12**, 1584–1593 PMID:26321638

- 46 Fourel, L., Valat, A., Faurobert, E., Guillot, R., Bourrin-Reynard, I., Ren, K. et al. (2016) B3 integrin-mediated spreading induced by matrix-bound BMP-2 controls Smad signaling in a stiffness-independent manner. *J. Cell Biol.* **212**, 693–706 PMID:26953352
- 47 Oelgeschläger, M., Larrain, J., Geissert, D. and De Robertis, E.M. (2000) The evolutionarily conserved BMP-binding protein twisted gastrulation promotes BMP signalling. *Nature* **405**, 757–763 doi:10.1038/35015500
- 48 Sawala, A., Sutcliffe, C. and Ashe, H.L. (2012) Multistep molecular mechanism for bone morphogenetic protein extracellular transport in the *Drosophila* embryo. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 11222–11227 doi:10.1073/pnas.1202781109
- 49 Winstanley, J., Sawala, A., Baldock, C. and Ashe, H.L. (2015) Synthetic enzyme-substrate tethering obviates the tolloid-ECM interaction during *Drosophila* BMP gradient formation. *eLife* **4**, e05508 doi:10.7554/eLife.05508
- 50 Entchev, E.V., Schwabedissen, A. and González-Gaitán, M. (2000) Gradient formation of the TGF- β homolog Dpp. *Cell* **103**, 981–992 doi:10.1016/S0092-8674(00)00200-2
- 51 Kicheva, A., Pantazis, P., Bollenbach, T., Kalaidzidis, Y., Bittig, T., Jülicher, F. et al. (2007) Kinetics of morphogen gradient formation. *Science* **315**, 521–525 doi:10.1126/science.1135774
- 52 Swaminathan, R., Hoang, C.P. and Verkman, A.S. (1997) Photobleaching recovery and anisotropy decay of green fluorescent protein GFP-S65T in solution and cells: cytoplasmic viscosity probed by green fluorescent protein translational and rotational diffusion. *Biophys. J.* **72**, 1900–1907 doi:10.1016/S0006-3495(97)78835-0
- 53 Belenkaya, T.Y., Han, C., Yan, D., Opoka, R.J., Khodoun, M., Liu, H. et al. (2004) *Drosophila* Dpp morphogen movement is independent of dynamin-mediated endocytosis but regulated by the glypican members of heparan sulfate proteoglycans. *Cell* **119**, 231–244 PMID:15479640
- 54 Han, C., Yan, D., Belenkaya, T.Y. and Lin, X. (2005) *Drosophila* glypicans Dally and Dally-like shape the extracellular Wingless morphogen gradient in the wing disc. *Development* **132**, 667–679 PMID:15647319
- 55 Rath, B., Nam, J., Deschner, J., Schaumburger, J., Tingart, M., Grässel, S. et al. (2011) Biomechanical forces exert anabolic effects on osteoblasts by activation of SMAD 1/5/8 through type 1 BMP receptor. *Biorheology* **48**, 37–48 PMID:21515935
- 56 Zhou, J., Lee, P.-L., Tsai, C.-S., Lee, C.-I., Yang, T.-L., Chuang, H.-S. et al. (2012) Force-specific activation of Smad1/5 regulates vascular endothelial cell cycle progression in response to disturbed flow. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 7770–7775 doi:10.1073/pnas.1205476109
- 57 Zhou, J., Lee, P.-L., Lee, C.-I., Wei, S.-Y., Lim, S.H., Lin, T.-E. et al. (2013) BMP receptor-integrin interaction mediates responses of vascular endothelial Smad1/5 and proliferation to disturbed flow. *J. Thromb. Haemost.* **11**, 741–755 PMID:23387849
- 58 Du, J., Chen, X., Liang, X., Zhang, G., Xu, J., He, L. et al. (2011) Integrin activation and internalization on soft ECM as a mechanism of induction of stem cell differentiation by ECM elasticity. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 9466–9471 doi:10.1073/pnas.1106467108
- 59 Guo, R., Lu, S., Merkel, A.R., Sterling, J.A. and Guelcher, S.A. (2016) Substrate modulus regulates osteogenic differentiation of rat mesenchymal stem cells through integrin β 1 and BMP receptor type IA. *J. Mater. Chem. B Mater. Biol. Med.* **4**, 3584–3593 PMID:27551426
- 60 Schwarz, C., Wulsten, D., Elinghaus, A., Lienau, J., Willie, B.M. and Duda, G.N. (2013) Mechanical load modulates the stimulatory effect of BMP2 in a rat nonunion model. *Tissue Eng. Part A* **19**, 247–254 PMID:22861354
- 61 Healey, E.G., Bishop, B., Elegheert, J., Bell, C.H., Padilla-Parra, S. and Siebold, C. (2015) Repulsive guidance molecule is a structural bridge between neogenin and bone morphogenetic protein. *Nat. Struct. Mol. Biol.* **22**, 458–465 PMID:25938661
- 62 Hagihara, M., Endo, M., Hata, K., Higuchi, C., Takaoka, K., Yoshikawa, H. et al. (2011) Neogenin, a receptor for bone morphogenetic proteins. *J. Biol. Chem.* **286**, 5157–5165 PMID:21149453
- 63 Kirkbride, K.C., Townsend, T.A., Bruinsma, M.W., Barnett, J.V. and Blobel, G.C. (2008) Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. *J. Biol. Chem.* **283**, 7628–7637 PMID:18184661
- 64 Scherner, O., Meurer, S.K., Tihaa, L., Gressner, A.M. and Weiskirchen, R. (2007) Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. *J. Biol. Chem.* **282**, 13934–13943 PMID:17376778
- 65 Jasuja, R., Allen, B.L., Pappano, W.N., Rapraeger, A.C. and Greenspan, D.S. (2004) Cell-surface heparan sulfate proteoglycans potentiate chordin antagonism of bone morphogenetic protein signaling and are necessary for cellular uptake of chordin. *J. Biol. Chem.* **279**, 51289–51297 doi:10.1074/jbc.M408129200
- 66 Viviano, B.L., Paine-Saunders, S., Gasiunas, N., Gallagher, J. and Saunders, S. (2004) Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. *J. Biol. Chem.* **279**, 5604–5611 doi:10.1074/jbc.M310691200